KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Short term Debt (2017 - 2025)

Novartis Ag's Short term Debt history spans 9 years, with the latest figure at $794.0 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 90.35% year-over-year to $794.0 million; the TTM value through Dec 2025 reached $794.0 million, down 90.35%, while the annual FY2025 figure was $794.0 million, 90.35% down from the prior year.
  • Short term Debt for Q4 2025 was $794.0 million at Novartis Ag, down from $8.2 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $8.2 billion in Q4 2024 and bottomed at $624.0 million in Q4 2023.
  • The 5-year median for Short term Debt is $863.0 million (2022), against an average of $2.6 billion.
  • The largest annual shift saw Short term Debt skyrocketed 1219.23% in 2024 before it plummeted 90.35% in 2025.
  • A 5-year view of Short term Debt shows it stood at $2.6 billion in 2021, then tumbled by 67.07% to $863.0 million in 2022, then dropped by 27.69% to $624.0 million in 2023, then surged by 1219.23% to $8.2 billion in 2024, then tumbled by 90.35% to $794.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVS's Short term Debt are $794.0 million (Q4 2025), $8.2 billion (Q4 2024), and $624.0 million (Q4 2023).